Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9933428 | 0.67 | ADRB1 (0.52) | — | |
| SCHEMBL9234686 | 0.66 | MAPT (0.46) | DAOAURKAAURKBINCENPMCL1 | |
| SCHEMBL28807259 | 0.65 | MAPT (0.49) | DAOAURKAAURKBINCENPMCL1 | |
| SCHEMBL4032846 | 0.62 | MAPT (0.47) | — | |
| SCHEMBL16180595 | 0.62 | CA2 (0.39) | — | |
| SCHEMBL924443 | 0.61 | HSD17B10 (0.41) | DAOAURKAAURKBINCENP | |
| SCHEMBL16862997 | 0.61 | POLB (0.50) | DAOAURKAAURKBINCENP | |
| SCHEMBL4785260 | 0.60 | AURKA (0.40) | DAOAURKAAURKBINCENP | |
| SCHEMBL27358098 | 0.60 | PDE3B (0.37) | DAOAURKAAURKBINCENPMCL1 | |
| SCHEMBL7977829 | 0.59 | CRBN (0.50) | DAOAURKAAURKBINCENPMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060241151-A1 | Pyrid-2-one derivatives and methods of use | AMGEN, INC. (US) | 2006-10-26 | — | — | US | disclosed |
| EP-1575947-A1 | 2-OXOPYRIDIN-3-YL THIA(DI)AZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CELL PROLIFERATION AND APOPTOSIS RELATED DISEASES | Amgen Inc. (US) | 2005-09-21 | — | — | EP | disclosed |
| US-20040147561-A1 | Pyrid-2-one derivatives and methods of use | SYNGENTA CROP PROTECTION AG (CH) | 2004-07-29 | — | — | US | disclosed |
| WO-2004060890-A1 | 2-OXOPYRIDIN-3-YL THIA (DI) AZOLE DERIVATES FOR USE IN THE TREATMENT OF CELL PROLIFERATION AND APOPTOSIS RELATED DISEASES | AMGEN INC. (US) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147561-A1 | Pyrid-2-one derivatives and methods of use | PLPBP, PNPO, PDXK | DAO 1222/4885AURKA 1772/4885AURKB 1079/4885 |
| US-20060241151-A1 | Pyrid-2-one derivatives and methods of use | PLPBP, PNPO, PDXK | DAO 1243/4885AURKA 1636/4885AURKB 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.